EGFR and non-small cell lung carcinoma: Treatment of EGFR-mutated NSCLC with EGFR-tyrosine kinase inhibitors (TKIs) is a model for biomarker-driven therapy and highlights the importance of establishing a predictive molecular biomarker for personalized therapy in the treatment of solid tumors [8].